NCT04233346 2025-04-04The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationOtsuka Beijing Research InstitutePhase 2 Active not recruiting93 enrolled
NCT05286528 2023-10-27Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund DatabasePfizerCompleted1,484 enrolled 6 charts
NCT03709017 2022-12-07Iclusig PMS in CML or Ph+ALL PatientsKorea Otsuka Pharmaceutical Co., Ltd.Unknown50 enrolled
NCT01667133 2022-06-13A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)TakedaPhase 1/2 Completed35 enrolled 36 charts
NCT00660920 2018-05-16Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesTakedaPhase 1 Completed81 enrolled
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts